Swiss pharmaceutical giant Novartis has signed an initial deal to produce the mRNA molecules for the Covid-19 vaccine developed by German biotech firm CureVac.
This content was published on
2 minutes
Keystone-SDA/jdp
Português
pt
Multinacional Novartis vai ajudar a produzir vacina CureVac Covid-19
On Thursday, Novartis said its plant in Kundl, Austria, would start production of the CureVac vaccine (CVnCoV) this summer. It hopes to deliver enough drug substance to produce 50 million doses by the end of the year and plans to accelerate production to reach 200 million doses in 2022. CureVac is also working with German pharmaceutical company Bayer to manufacture its vaccine.
“We are currently expanding our site with additional capacities for the production of mRNA in order to best serve the increasing demand,” said Steffen Lang, Global Head of Novartis Technical Operations, in a press release.
At the end of January, Novartis announced it would also provide manufacturing capacity for Pfizer/BioNTech’s Covid-19 vaccine. Under the deal, Novartis is involved in the fill-and-finish process – taking the bulk mRNA active ingredient from BioNTech and putting it into vials at its facility in Stein, Switzerland.
Novartis says it is considering other agreements to support the global supply of Covid-19 vaccines and therapeutics.
Switzerland has reserved over 30 million vaccine doses from different manufacturers – Pfizer/BioNTech, Moderna, AstraZeneca, Curevac and Novavax – for its population of 8.6 million people. So far, there are two vaccines approved and available in the country, those from Pfizer/BioNTech and Moderna.
The Swiss government secured 5 million doses of the CureVac vaccine in February. It is based on similar mRNA technology as the Pfizer/BioNtech and Moderna vaccines. Swiss firm Lonza is producing the main active vaccine ingredients for the Moderna vaccine for non-US markets at its site in Visp in southern Switzerland.
Swiss football boss wants crackdown on individual hooligans
This content was published on
The head of the Swiss Football League says he prefers a harsher approach to individual hooligans rather than collective punishment measures affecting all fans.
Amherd: Council of Europe is ‘as urgently needed as ever’
This content was published on
The Swiss government emphasised on Sunday the vital role of the Strasbourg-based Council of Europe, 75 years after it was founded.
Swiss minister: Italy will back Switzerland in EU talks
This content was published on
Bern can count on the backing of Italy as it re-enters talks with the European Union on future relations, Viola Amherd says.
Student protestors at University of Lausanne continue pro-Palestine sit-in
This content was published on
Since Thursday, a hall on campus has been occupied by students calling for a boycott of Israeli academic institutions and a ceasefire in Gaza.
This content was published on
Swiss public broadcasters RTS and SRF are drastically reducing their communications via the social network X (formerly Twitter).
Israel: president of Swiss universities rejects academic boycott
This content was published on
Luciana Vaccaro, president of Swissuniversities, the umbrella group of Swiss universities, is not in favour of an academic boycott of Israeli universities.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
Novartis agrees to help Pfizer-BioNTech produce Covid-19 vaccine
This content was published on
Swiss pharma giant Novartis says it has signed an initial agreement to provide manufacturing capacity for Pfizer and BioNTech's Covid-19 vaccine.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.